Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
| Autor: | Judith Hsia, John T. Monyak, Paul M. Ridker, Jean G. MacFadyen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Cholesterol business.industry law.invention Surgery Rosuvastatin Calcium chemistry.chemical_compound chemistry Randomized controlled trial law JUPITER trial Internal medicine Cohort medicine lipids (amino acids peptides and proteins) Rosuvastatin Cardiology and Cardiovascular Medicine Adverse effect business medicine.drug Cohort study |
| Zdroj: | Journal of the American College of Cardiology. 57:1666-1675 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2010.09.082 |
| Popis: | Objectives The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels Background The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current recommended targets remain uncertain. Methods A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C Results During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C Conclusions Among adults with LDL-C |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|